RAD 140
What it is Origin Mechanism Effects Risks FAQ
{{ ctaLabel }}
SARM/RAD140/Testolone

The oral compound that never finished a human trial.

RAD140 was built as a drug candidate, sold as a research chemical, and adopted by lifters before anyone finished asking whether it is safe. Here is what the record actually contains, the pharmacology, the trial that stopped, the case reports, and where the honest gaps are.

See the above-board route Start with the pharmacology

No dosing, sourcing, or protocols anywhere on this page. Educational reference only.

Class
Nonsteroidal SARM
Developed by
Radius Health (2010s)
Route
Oral, non-methylated
Human data
One Phase 1 oncology trial
Status
Not approved · WADA banned
01 / What it is

Not a steroid. Not a drug, either. Not yet.

Testolone is a selective androgen receptor modulator: a small nonsteroidal molecule that binds the same receptor testosterone does, but with a different shape and a different downstream signature in each tissue.

Anabolic steroids are testosterone derivatives. They flood every androgen receptor in the body and are also converted into estrogen and DHT, which is where much of the hair, prostate and cardiovascular cost comes from. RAD140 is not in that chemical family at all, it is an agonist at the androgen receptor that was engineered to favour muscle and bone over prostate and skin.

That is the design intent, and in animal models it broadly held. It is not the same claim as "safe in humans." Tissue selectivity is a ratio measured in rodents and primates; it does not remove the receptor from your pituitary, your liver, or your lipid metabolism.

"Selective" describes where the molecule prefers to act. It says nothing about what happens everywhere else it still acts.
02 / Origin

It was built for cancer patients, not for a cut.

The compound came out of a pharmaceutical programme aimed at androgen-receptor-positive breast cancer and at muscle-wasting conditions, populations where losing lean mass is a mortality risk.

Radius Health advanced testolone into a Phase 1 study in women with AR-positive metastatic breast cancer. That is the entire human clinical footprint of the molecule: a small, early-phase, oncology-population trial. The programme did not continue to late-phase work, and no regulator has ever approved RAD140 for any indication in any country.

Everything else (the forum logs, the before-and-afters, the "research chemical" listings shipped in dropper bottles) happened outside that process, in a market with no manufacturing oversight and no adverse-event reporting.

Intended indications
AR-positive breast cancer Cancer cachexia Age-related muscle loss Hormone therapy research
03 / Mechanism

One receptor, four different answers.

The receptor is the same in every tissue. What differs is the co-regulator machinery that assembles around it, which is why a single molecule can read as strongly anabolic in muscle and weakly androgenic in the prostate.

Step 01
Binds the AR
Testolone occupies the androgen receptor in place of testosterone, with high affinity and no conversion to estrogen or DHT.
Step 02
Recruits differently
The bound complex pulls a different set of co-activators than a steroid does, the structural basis of the claimed tissue selectivity.
Step 03
Muscle and bone respond
In preclinical models, anabolic gene programmes in skeletal muscle and bone activate at doses that leave prostate tissue comparatively quiet.
Step 04
The axis reads it as androgen
Your hypothalamus and pituitary do not care about selectivity. They register androgen signal and dial down your own LH, FSH and testosterone production.
04 / Reported effects

What people report, and what the evidence behind it is.

Each claim below is tagged with where it comes from. Almost nothing here rests on a controlled trial in healthy adults, because no such trial exists.

Read this first

Regulators have warned that SARMs sold outside clinical use carry risks of liver injury and cardiovascular events, and published case reports describe drug-induced liver injury in otherwise healthy young men using RAD140. Suppression of your own testosterone is the expected outcome, not an edge case.

Lean mass
The consistent claim: several kilos of lean tissue over a short block, with strength rising faster than bodyweight.
Animal data Anecdote
Strength expression
Users describe rapid strength gains in the first weeks, earlier than hypertrophy alone would explain.
Anecdote only
Bone density
Preclinical work showed improved bone mineral density and cortical strength, part of the original osteoporosis rationale.
Animal data
Testosterone suppression
Reduced LH, FSH and total testosterone. Documented in human case reports; recovery time is not characterised.
Human reports
Liver enzymes
Case reports of marked ALT/AST elevation and cholestatic injury, including hospitalisation, in young men with no other risk factors.
Human reports
Lipids and blood pressure
HDL reduction is commonly reported across the SARM class; long-term cardiovascular consequence is unstudied.
Class-level Unquantified

"Animal data" = rodent or primate studies. "Human reports" = published case reports or small early-phase data, not controlled efficacy trials. "Anecdote" = self-reported, unverified, unblinded, and usually alongside other compounds.

05 / Reported timeline

The order things tend to appear in.

This sequence is assembled from self-reports, not from trial data, and the unwanted changes arrive on the same clock as the wanted ones. It is a description, not a schedule to follow.

Week 1–2
Strength and drive

Earliest reports are neural rather than structural: better session output, higher aggression, occasional sleep disruption.

Week 2–4
Mass, and the first labs

Visible lean gain in reports, and the window in which suppression and liver-enzyme changes start showing on bloodwork.

Week 4–8
Low-testosterone symptoms

Libido loss, fatigue and mood flattening as endogenous production falls. Lethargy is among the most frequently described complaints.

After stopping
An unmeasured recovery

How long the axis takes to return is not established in any study. Some retained mass is reported; so is prolonged suppression.

06 / The comparison

RAD140 is not the only route to a bigger anabolic signal.

Three paths get compared in the same conversation. They differ less in whether they work than in whether anyone will put their name on what is in the bottle.

Option A
Anabolic steroids
Decades of use and a well-mapped side-effect profile: estrogenic and DHT-mediated effects, cardiovascular and hepatic load, injectable in most cases. Known quantity, high cost.
Controlled substance
Option B
RAD140, grey market
Oral, cheap, sold as "not for human consumption." Independent analyses of SARM products have repeatedly found mislabelled contents, wrong compounds and undeclared actives. You cannot audit what you are taking.
Unapproved No oversight
Recommended
Option C
The above-board route
Compounds and products that are legal to sell for human use, made by a company whose name is on the label, and built on molecules that actually finished their human research. Less exciting than a forum protocol, and the only column where the unknowns are not doing the heavy lifting.
What it is   A known molecule
Human data   Completed trials
Sold as   A labelled product for human use
07 / The omissions

What the sales pages leave out.

None of the following is fringe. It is the part of the profile that sits underneath a photograph of a lean torso and a discount code.

Regulatory position

Public health agencies have issued advisories against SARM use outside clinical trials, citing liver injury and cardiovascular risk, and enforcement letters have gone to companies marketing them as supplements. RAD140 is also prohibited in sport at all times.

01
Suppression is the baseline, not the risk

Every androgen agonist shuts down the axis it imitates. Recovery timelines for RAD140 have never been formally characterised, and no post-cycle protocol has been validated for it.

02
Liver injury in healthy young men

Published cases describe severe hepatotoxicity after weeks of use, with jaundice and months-long recovery. "Non-methylated, so liver-safe" does not survive the case literature.

03
You are not taking what the label says

Analytical surveys of SARM products found a substantial share misidentified, underdosed, overdosed, or containing entirely different compounds, including unapproved drugs.

04
The long-term column is empty

There is no multi-year safety data in healthy adults, because the molecule never ran that study. Absence of reported harm at ten years is not evidence of safety at ten years.

05
A positive test ends careers

RAD140 is detectable long after the last dose and is a recurring cause of sanctions in tested sport, including in athletes who say they took a contaminated supplement.

The takeaway

You want the result. You do not want the unknowns.

Strength, lean mass and recovery do not require a molecule whose safety column is blank. There are routes where the research was finished, the product is legal to sell for human use, and the company behind it is identifiable. That is a lower ceiling on risk, not on results.

{{ ctaLabel }}

Start with what is printed on the label and who printed it.

08 / Straight answers

Questions people actually ask.

{{ item.q }}

{{ item.a }}

RAD 140

An independent reference on testolone: the pharmacology, the clinical record, the gaps, and the above-board alternatives.

Educational content only. Nothing here is medical advice, a recommendation to obtain or use RAD140, or an offer to sell any compound. RAD140 (testolone) is not approved by any medical regulator for human use, is not a dietary supplement, and is prohibited in sport at all times by the World Anti-Doping Agency. Statements about reported effects describe published case reports, preclinical studies or self-reported user accounts as labelled, and are not claims of efficacy or safety. Speak with a licensed physician about hormonal health before making any decision.

© 2026 · Reference page · No products sold.